Which therapy will work best for you?

The answer depends on many factors, including your health, other medications you take, and whether your osteoarthritis case is mild, moderate or severe. The earlier you and your doctor work together, the sooner you can begin a treatment plan that is right for you.

Using the osteoarthritis self-assessment tool below can help you prepare to discuss your symptoms.

 

Assesment tool

1. Kde pociťujete bolesť kĺbov?

1. Kde pociťujete bolesť kĺbov? *

2. Ako dlho pociťujete bolesť kĺbov?

2. Ako dlho pociťujete bolesť kĺbov? *

3. Poranili ste si nedávno postihnutý kĺb?

3. Poranili ste si nedávno postihnutý kĺb? *

4. Ako by ste bolesť kĺbov ohodnotili na stupnici od 1 (žiadna bolesť) do 10 (neznesiteľná bolesť) počas odpočinku?

*
(1 = žiadna bolesť)(10 = najhoršia predstaviteľná bolesť)

5. Ako by ste bolesť kĺbov ohodnotili na stupnici od 1 (žiadna bolesť) do 10 (neznesiteľná bolesť) počas aktivity?

*
(1 = žiadna bolesť)(10 = najhoršia predstaviteľná bolesť)

6. Ktoré každodenné aktivity sú pre vás v dôsledku bolesti kĺbov ťažšie (ak existujú)?

7. Aké typy liečby na zmiernenie bolesti kĺbov ste vyskúšali? Začiarknite všetky, ktorých sa to týka.

*

8. Napuchol vám alebo sa zväčšil niekedy kĺb?

*

9. Bola vám lekárom alebo iným zdravotníckym odborníkom diagnostikovaná osteoartróza?

*

10. Aké máte ciele alebo očakávania od liečby?

Summary of Indications for Use

DUROLANE (3 mL): Argentina, Australia,* Brazil, Chile, Colombia, EU,* India, New Zealand,* Russia, Switzerland,* Turkey,* United Arab Emirates: Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been approved in Australia, EU and New Zealand for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers, and toes.

Mexico: Symptomatic treatment of mild to moderate knee osteoarthritis.

Taiwan: Treatment of pain in OA of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen. In addition, DUROLANE has been licensed for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, fingers and toes.

*DUROLANE is also indicated for pain following joint arthroscopy in the presence of osteoarthritis within 3 months of the procedure.

Full prescribing information can be found in product labeling.

Summary of risks: You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children. Risks can include transient pain, swelling and/ or stiffness at the injection site.

Full prescribing information can be found on the product labeling.

Summary of Indications for Use for Curavisc: Curavisc (2 mL): EU, Brazil, Egypt, Malaysia: Pain and disturbed function in degenerative and traumatic disease of the joints. Curavisc can be used for large joints, e.g., knee, hip, or shoulder joint. Treatment course of 3- injections, up to 5- injections.

Summary of risks: You should not use CURAVISC if you have infections or skin disease at the injection site. CURAVSIC has not been tested in pregnant or lactating women, or children. Risks can include transient pain, swelling and/ or stiffness at the injection site.

Full prescribing information can be found on the product labeling and on the website at bioventus.com/curavisc.com.